As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
The Anatolian Journal of Cardiology
Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin? [Anatol J Cardiol]
Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?
Suna Kıraç1Pamukkale Üniversitesi Tıp Fakültesi Nükleer Tıp Anabilim Dalı, Denizli, Türkiye
Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?
Suna Kıraç1Pamukkale Üniversitesi Tıp Fakültesi Nükleer Tıp Anabilim Dalı, Denizli, Türkiye
Suna Kıraç. Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anatol J Cardiol. 2007; 7(2): 214-215 Manuscript Language: English